



THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED
JUL 12 2002
TECH CENTER 1600/2900

In re Application of:

Bernd Riedl et al.

Examiner: James Reamer

Serial No.: 10/042,226

Group Art Unit: 1614

Filed: January 11, 2002

Title: ω -CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE
INHIBITORS

H/S
Harmon
7/16/02

RESPONSE TO RESTRICTION REQUIREMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In response to the election of species requirement, Applicants elect with traverse, methods which employ the compound 42 in Table 4 on page 86, "N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea."

Claims 1-3, 6-13, 15, 17-19, 21, 28, 32, 33, 37-39, 44-50, 52-54 and 68-83 encompass the elected species.

Applicants submit the examination should be extended to the use of all compounds within formula I in the treatment of cancerous cell growth mediated by RAF kinase.

There is no evidence of an undue burden to examine method claims with these features.

An Information Disclosure Statement was filed on June 7, 2002. Co-pending applications related to this application include:


Bayer 15A - 09/889,227

Bayer 15C1 - 09/948,915

Bayer 15P3 - 09/777,920

Bayer 25A - 10/042,203
Bayer 29 - 09/907,970
Bayer 18A - 09/993,647
Bayer 15P4 - 10/071,248
Bayer 17V1 - 60/354,950
Bayer 34V1 - 60/334,950
Bayer 35V1 - 60/354,937
Bayer 37V1 - 60/354,935

Respectfully submitted,



Richard J. Traverso (Reg. No. 30,595)
Attorney/Agent for Applicant(s)

MILLEN, WHITE, ZELANO
& BRANIGAN, P.C.
Arlington Courthouse Plaza 1, Suite 1400
2200 Clarendon Boulevard
Arlington, Virginia 22201
Telephone: (703) 243-6333
Facsimile: (703) 243-6410

Attorney Docket No.: BAYER 24A

Date: July 11, 2002

RJT/lvb
K:\Bayer\24A\resp to restr req 7-11-02.dot